Medtronic
Medtronic plc is a global technology company and a dominant force in the Insulin Delivery Devices market, renowned for pioneering hybrid closed-loop technologies and sensor-augmented pump systems. Founded in 1949, the company is today the world’s largest medical technology company. In the diabetes sector, Medtronic focuses on integrated patient monitoring and automated insulin delivery (AID) platforms. Their flagship product is the MiniMed 780G system, a hybrid closed-loop system that continuously monitors blood sugar levels using a Continuous Glucose Monitor (CGM) and automatically adjusts insulin delivery via the insulin pump. Users only need to input meal-time bolus doses. Medtronic also offers the InPen™ smart insulin pen, which connects to a mobile app for dose calculations, tracking, and CGM system integration for patients on Multiple Daily Injections (MDI). By integrating advanced predictive algorithms and offering long-wear infusion sets, Medtronic continues to enhance glycaemic control workflows and solidify its position as a top player driving innovation in the automated insulin delivery segment.
Latest Market Research Report on Insulin Delivery Devices Download PDF Brochure Now
Insulet Corporation
Insulet Corporation, headquartered in Massachusetts and founded in 2000, is a key innovator specializing in tubeless patch pumps, particularly through its Omnipod Insulin Management System. The company’s mission is to simplify life for people with insulin-dependent diabetes by offering a unique alternative to traditional delivery methods. Insulet offers a line of tubeless, wearable, Pod-based systems, including the Omnipod 5 Automated Insulin Delivery (AID) system. The Pod is a discreet, waterproof, disposable device that provides continuous insulin delivery for up to three days without annoying tubes. Omnipod 5 integrates with CGMs and uses automated insulin adjustments to help keep users in range day and night, reducing A1c and improving time in range. Recognized as the number one prescribed AID in the U.S. in 2024, Insulet’s focus on ease of use, convenience, and a high degree of automation gives it a competitive edge, driving adoption across Type 1, Type 2, and pediatric patient groups globally.
Novo Nordisk A/S
Novo Nordisk A/S, founded in Denmark in 1923, is a global pharmaceutical and healthcare company and a long-standing leader in diabetes care, dominating the insulin delivery device market, particularly the insulin pen segment. Insulin pens represented the largest share of the overall market in 2024, a segment where Novo Nordisk is a leader. The company specializes in providing solutions for personalized treatment guidance and is focused on increasing the availability of connected pens. Their advanced offerings include the NovoPen® 6 and NovoPen Echo® Plus, which are smart insulin pens that automatically record and track insulin dosing information with each injection. These smart pens connect with compatible apps, like the Dose Check titration app (developed in partnership with Amalgam Rx), designed for patients with Type 2 diabetes initiating or switching insulin. Novo Nordisk’s strategy involves heavy investment in connected ecosystems and integrated platforms, leveraging its strong global footprint and history in diabetes innovation to maintain its leadership in insulin delivery solutions.
Tandem Diabetes Care, Inc.
Tandem Diabetes Care, Inc. specializes in advanced Automated Insulin Delivery (AID) systems, recognized for its user-centric, sleek, and slim touchscreen insulin pumps. The company is a strong presence in advanced pump therapy, providing products like the t:slim X2 and the compact Tandem Mobi pump. These systems are powered by Control-IQ+ technology, a predictive algorithm featuring AutoBolus capability that predicts and helps prevent both highs and lows, and is available for both Type 1 and Type 2 diabetes patients (ages 2+ and 18+, respectively). Tandem focuses on seamless interoperability, allowing its pumps to integrate with multiple Continuous Glucose Monitors (CGMs), such as the FreeStyle Libre 3 Plus sensor. This commitment to connectivity and advanced, algorithm-driven automation helps optimize therapy and improve patient outcomes, simplifying diabetes management and allowing users to focus less on their condition. The company actively seeks to expand its portfolio, having acquired AMF Medical to incorporate insulin patch pumps.
Abbott Laboratories
Abbott Laboratories is a prominent global healthcare company leveraging its long history in diagnostics to maintain a significant presence in the diabetes management space, particularly through its glucose monitoring and insulin delivery enabling systems. While Abbott may be primarily known for its FreeStyle Libre Continuous Glucose Monitoring (CGM) products, which use “flash” technology to measure glucose in interstitial fluid, these devices are foundational components in the Automated Insulin Delivery (AID) ecosystem. The company offers blood and glucose monitoring systems, sensors, and data management software essential for patients using insulin delivery devices. Abbott’s FreeStyle Libre sensors are increasingly integrated with third-party insulin pumps and smart pens via interoperability agreements, such as its OEM agreement with Medtronic to develop CGMs for use with their insulin pumps and pen systems. This integration supports the goal of highly precise, user-friendly, and decentralized diabetes care.
F. Hoffmann-La Roche Ltd
F. Hoffmann-La Roche Ltd (Roche) is a major pharmaceutical and diagnostics industry giant that provides comprehensive diabetes care solutions through its Roche Diabetes Care division, leveraging nearly five decades of experience. The company offers a range of products, including blood glucose meters, lancing devices, data management systems, and software. In insulin delivery, Roche focuses on advanced sensor-augmented pumps and cloud-connected diabetes management tools, such as the Accu-Chek Insight Insulin Pump. Roche is actively enhancing its integrated solutions through digital health and AI, exemplified by the launch of mySugr Pump Control, which simplifies pump therapy through a smartphone, and plans for the development of its own CGM, the Accu-Chek Smartguide, which will set the stage for full integration with their insulin pumps. This strategy aims to improve the accuracy of insulin delivery and patient confidence, supporting proactive glycaemic management across multiple care settings.
Eli Lilly and Company
Eli Lilly and Company is a key player in the diabetes care market, known both as a major insulin manufacturer and a provider of integrated delivery solutions. The company maintains a strong presence through its range of prefilled insulin pens and is rapidly advancing its smart delivery systems and connected ecosystems. Eli Lilly focuses on accessibility and patient-centric design, often emphasizing affordability and ensuring its devices are widely accessible across diverse healthcare settings. The company offers leading smart pen ecosystems that track doses and connect to diabetes apps. Furthermore, Eli Lilly is actively engaged in strategic collaborations, such as its partnership with IABL to supply active pharmaceutical ingredients for human insulin at a reduced price, demonstrating a commitment to increasing patient access and affordability for high-quality insulin and integrated delivery technology.
Sanofi
Sanofi is a significant global pharmaceutical company with a strong legacy in diabetes management, particularly recognized for its reliable and widely used insulin pen platforms. The company is one of the key manufacturers of multiple insulin pen platforms, offering both refillable and disposable options that contribute significantly to the insulin pen segment—the largest product segment in the market. Sanofi focuses on long-acting insulin formulations and the simplicity of its device design, which caters effectively to both developed and emerging markets. The company actively integrates its offerings with public health programs, and its products are increasingly moving towards ‘smart connected pens,’ which are becoming standard, especially for Type 2 patients initiating insulin therapy. By focusing on robustness, simplicity, and widespread accessibility, Sanofi secures its position as a major manufacturer and supplier in the global insulin delivery device market.
Latest Market Research Report on Insulin Delivery Devices Download PDF Brochure Now